Institute of Hematology & Blood Diseases Hospital, China: Anemia, Hemolytic, Autoimmune trials

The registry lists 16 Anemia, Hemolytic, Autoimmune studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 12 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 7Phase 2 4No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07816341Phase 1
• META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07689604Early Phase 1
• IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07585071Phase 1
• Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRSRecruitingNCT07578675
• National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic AnemiaRecruitingNCT07019038
• Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic AnemiaRecruitingNCT06921980
• A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT06770504Phase 1
• CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.RecruitingNCT06733610Phase 1
• CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of TherapyRecruitingNCT06212154Phase 1
• The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaRecruitingNCT06021977Phase 2
• Anti-CD38 Antibody Treating Evans SyndromeRecruitingNCT06014775Phase 2
• National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
• CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.Active, not recruitingNCT06231368Phase 1
• PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of TherapyTerminatedNCT05676697Phase 1
• The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaActive, not recruitingNCT04398459Phase 2
• Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.Status unknownNCT01579110Phase 2